Possible CK1α-targeted therapies, which will likely rely on p53 activity, can be hypothetically effective in approx. 80% of AML with wt TP53 but can be also synergistic with the approaches focused on the restoration of mutant p53 function [126,127]. Here, TP53 is linked to acute myeloid leukemia.